Deargen Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
39
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$16.7M
- Investors
-
8
Deargen General Information
Description
Developer of an artificial intelligence-based drug discovery platform designed to maximize the efficiency of new drug development. The company's platform advances the treatment of rare and intractable diseases through the integration of artificial intelligence and collective intelligence and specializes in genome data analysis, biomarker prediction, molecule selection, and optimization, enabling clinicians to realize precision medicine by designing small molecules for new drugs.
Contact Information
Website
www.deargen.me(Operating Subsidiary)
Corporate Office
- 136, Cheongsa-ro
- R1846, 18th Floor
- Daejeon, Seo-gu
- South Korea
Corporate Office
- 136, Cheongsa-ro
- R1846, 18th Floor
- Daejeon, Seo-gu
- South Korea
Deargen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 24-Feb-2022 | $16.7M | Completed | Startup | ||
| 6. Later Stage VC (Series A) | 01-Jan-2021 | Completed | Startup | |||
| 5. Merger/Acquisition | 02-Nov-2020 | Completed | Startup | |||
| 4. Seed Round | 26-Oct-2020 | Completed | Startup | |||
| 3. Accelerator/Incubator | 01-Jan-2020 | Completed | Startup | |||
| 2. Accelerator/Incubator | 15-Nov-2018 | $700K | $700K | Completed | Startup | |
| 1. Accelerator/Incubator | 15-Jun-2017 | Completed | Startup |
Deargen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Deargen Patents
Deargen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025165142-A1 | Method for generating molecule on basis of reinforcement learning model | Pending | 01-Feb-2024 | ||
| WO-2025095409-A1 | Molecular fragment-based molecule generation method | Inactive | 01-Nov-2023 | ||
| WO-2024172241-A1 | Method of training protein structure prediction model | Inactive | 17-Feb-2023 | ||
| US-20240282408-A1 | Method for predicting protein binding site | Pending | 16-Feb-2023 | ||
| WO-2024167094-A1 | Method for predicting protein structure by using twist-based structure updating | Inactive | 06-Feb-2023 | G16B40/20 |
Deargen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Deargen Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tech Incubator Program for Startup | Accelerator/Incubator | Minority |
Deargen FAQs
-
When was Deargen founded?
Deargen was founded in 2016.
-
Where is Deargen headquartered?
Deargen is headquartered in Daejeon, South Korea.
-
What is the size of Deargen?
Deargen has 39 total employees.
-
What industry is Deargen in?
Deargen’s primary industry is Drug Discovery.
-
Is Deargen a private or public company?
Deargen is a Private company.
-
What is Deargen’s current revenue?
The current revenue for Deargen is .
-
How much funding has Deargen raised over time?
Deargen has raised $22.1M.
-
Who are Deargen’s investors?
Tech Incubator Program for Startup has invested in Deargen.
-
When was Deargen acquired?
Deargen was acquired on 24-Feb-2022.
-
Who acquired Deargen?
Deargen was acquired by Amyloid Solution.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
